Optimer Nets $51.5M
San Diego-based Optimer Pharmaceuticals, the developer of an antibiotic for a dangerous hospital infection, said today it has raised $51.5 million through a secondary stock offering after deducting expenses. The company (NASDAQ: OPTR) sold about 4.9 million shares of common stock at $11 a share. Jefferies & Co. was the sole book-running manager in the offering. Last month, Optimer said its fidaxomicin drug candidate passed its second pivotal test against C.difficile bacterial infections, and that it plans to apply for FDA approval of the drug in the second half of 2010.